Reported Sunday, Aadi Bioscience Presented New Subgroup Analysis Of Patients With Advanced Malignant PEComa Of Gynecologic Origin Treated With Nab-Sirolimus At Society Of Gynecologic Oncology
Reported Sunday, Aadi Bioscience Presented New Subgroup Analysis Of Patients With Advanced Malignant PEComa Of Gynecologic Origin Treated With Nab-Sirolimus At Society Of Gynecologic Oncology
週日報道，Aadi Bioscience在婦科腫瘤學會發布了對接受Nab-Sirolimus治療的晚期婦科惡性PECOMA患者的新亞組分析
- Subgroup experienced efficacy and safety consistent with overall study population
- Advanced malignant PEComa tumors of gynecologic origin accounted for more than half of the evaluable patients enrolled in AMPECT
- Additional data presented highlight nab-sirolimus as potential approach for mTOR-driven gynecologic cancers
- 亞組的療效和安全性與總體研究人群一致
- 在參加AMPECT的可評估患者中，來自婦科的晚期惡性PeCOMA腫瘤佔一半以上
- 提供的其他數據表明，nab-sirolimus是治療MTOR驅動的婦科癌症的潛在方法
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。